Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The deal brings Labcorp’s U.S. portfolio—including biocompatibility, microbiological, and analytical testing, as well as preclinical research—under NAMSA’s roof
GlideTech materials are available in several standard base resins and offer customization options for specific applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The NP resin portfolio, indicated by its UL746G-certified prefix, equips manufacturers across industries to meet increasingly stringent regulatory and performance standards
These building blocks are essential to modern therapeutics, including fast-growing GLP-1 treatments for weight loss and diabetes
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
Subscribe To Our Newsletter & Stay Updated
